02 Aug The Law is Clear: There’s No Legal Authority to Control Prices Via Bayh-Dole
Paul Michel
RealClearPolicy, 8/2/2022 ...
Op-Eds
02 Aug Three Letters Summarize the March-In/ Compulsory Licensing Debate
Joe Allen
IPWatchdog, 8/1/2022 ...
27 Jun Ivy League profs taking potshots at patents imperil innovation
Wolfgang Klietmann
Boston Herald, 6/27/2022 ...
14 Jun The Bayh-Dole System Just Keeps Rollin’ Along – Despite Attempts to Throw it Off Track
Joe Allen
IP Watchdog, 6/14/2022...
13 Jun Drug Patent Seizures Put American Innovation at Needless Risk
Karen Kerrigan
RealClearHealth, 6/13/2022
...
07 Jun Revoking drug patents will cost Californians their lives and San Francisco biotech startups their motivation
Howard Dean
San Francisco Examiner, 6/7/2022...
31 May DOE’s Misuse of Bayh-Dole’s ‘Exceptional Circumstances’ Provision: How Uniform Patent Policies Slip Away
Joseph Allen
IPWatchdog, 5/26/2022 ...
26 May Using Bayh-Dole for cancer drug march-in rights is wrong
David Kappos
Law360, 5/25/2022 ...
26 May Prostate Drug Price Controls Come at Too High a Cost
Craig Garthwaite
RealClearPolicy, 5/26/2022 ...
06 Apr Removing patent rights to lower drug costs is dangerous precedent
Walter G. Copan
Denver Post, 4/6/2022 ...